ACE2 and COVID-19: Most COVID‐19 patients seroconvert within 7‐14 days of infection, with neutralizing antibodies that block the interaction between the “spike” glycoprotein of SARS‐CoV‐2 and its cellular receptor angiotensin‐converting enzyme 2 (ACE‐2) detected in the vast majority of recovered individuals.